Sildenafil in Canine Megaesophagus: Can It Improve Clinical Outcomes?

Megaesophagus (ME) continues to be one of the most frustrating esophageal disorders encountered in small animal practice. Characterized by reduced to absent esophageal motility and progressive esophageal dilation, ME remains the most common cause of regurgitation in dogs¹. Despite supportive management, affected dogs frequently develop complications such as malnutrition, dehydration, esophagitis, and aspiration pneumonia, contributing to a guarded to poor prognosis. Previous studies have reported survival times of only 1–3 months after diagnosis, with mortality rates approaching 74%². 

Because current treatment strategies largely revolve around lifelong feeding modification and supportive care, there has been increasing interest in therapies capable of improving esophageal transit itself. A recent randomized crossover study evaluating compounded liquid sildenafil has added an interesting perspective to the management discussion. 

Why Sildenafil? 

Sildenafil, a phosphodiesterase-5 inhibitor commonly used for pulmonary hypertension, has documented smooth muscle–relaxing effects on the gastroesophageal sphincter (GES). In human medicine, sildenafil has been investigated in achalasia, a disorder characterized by impaired esophageal peristalsis and incomplete relaxation of the lower esophageal sphincter. 

Researchers hypothesized that even though dogs with ME do not typically exhibit classic achalasia, relaxation of the GES could potentially facilitate faster passage of food into the stomach and reduce regurgitation episodes. 

The study aimed to evaluate whether compounded liquid sildenafil could²: 

• Reach the stomach effectively in dogs with ME  

• Improve esophageal clearance of food and liquids  

• Reduce regurgitation frequency  

• Improve body weight and quality of life  

Dogs received sildenafil at 1 mg/kg every 12 hours immediately before feeding, and videofluoroscopy was used to evaluate esophageal transit in real time². 

What Did the Study Find? 

One of the most clinically relevant findings was that dogs receiving sildenafil experienced significantly fewer regurgitation episodes compared with baseline and placebo periods. In addition, body weight increased significantly during sildenafil treatment. 

For clinicians managing ME cases, this finding is important. Chronic weight loss and poor body condition are major contributors to declining quality of life and owner decisions regarding euthanasia. Even modest improvements in nutritional retention may therefore carry clinical significance in selected patients. 

However, the improvements observed were relatively small overall, and not all dogs responded similarly. 

Interestingly, the study found no significant differences in videofluoroscopic clearance times between sildenafil and placebo groups. Likewise, owner-perceived quality of life scores did not improve significantly during treatment². 

The Challenge of Drug Delivery in Megaesophagus² 

One of the most valuable practical insights from the study involved medication delivery itself. 

Despite using a liquid formulation, sildenafil frequently failed to reach the stomach before feeding. In several dogs, the medication remained pooled within the dilated esophagus until slurry feeding was initiated afterward. 

This highlights a clinically important point: even liquid medications may not transit reliably in dogs with severe ME. 

The authors suggested several possible explanations for the variable response: 

• Retention of saliva or fluid within the esophagus  

• Differences in hydrostatic pressure  

• Variable severity of esophageal dysfunction  

• Delayed or inconsistent drug absorption  

To improve transit, owners were instructed to administer the medication in an upright position and feed within 2–5 minutes afterward². 

Safety and Compounding Concerns² 

Encouragingly, sildenafil was well tolerated at the study dose of 1 mg/kg every 12 hours, with no significant adverse effects reported. This is particularly relevant in ME patients, where medications causing nausea or vomiting can significantly worsen aspiration risk and nutritional compromise. 

However, the study also raised concerns regarding compounded formulations. Researchers later discovered the liquid sildenafil used had been prepared from bulk sildenafil powder rather than an FDA-approved finished drug product. 

This distinction is clinically important because compounded preparations made from bulk agents may demonstrate variable potency, absorption, and bioavailability. The authors noted that this variability may have contributed to inconsistent clinical responses. 

Given the widespread use of compounded medications in veterinary medicine, particularly for patients unable to swallow tablets, clinicians should verify the source and preparation standards of compounded sildenafil formulations whenever possible. 

What Does This Mean for Clinical Practice? 

This study does not establish sildenafil as a definitive treatment for canine ME. However, it does suggest that sildenafil may benefit selected patients by reducing regurgitation frequency and supporting weight gain. 

At present, sildenafil may be worth considering in dogs: 

• With persistent regurgitation despite optimized feeding management  

• Experiencing progressive weight loss  

• Able to tolerate consistent upright medication administration  

Importantly, clinicians should continue emphasizing that ME management still depends primarily on meticulous feeding protocols, aspiration pneumonia prevention, and realistic long-term owner expectations. 

References 

1. Nakagawa T, Doi A, Ohno K, Yokoyama N, Tsujimoto H. Clinical features and prognosis of canine megaesophagus in Japan. Journal of Veterinary Medical Science. 2019;81(3):348-52. https://www.jstage.jst.go.jp/article/jvms/81/3/81_18-0493/_pdf 

2. Mehain SO, Haines JM, Guess SC. A randomized crossover study of compounded liquid sildenafil for treatment of generalized megaesophagus in dogs. American Journal of Veterinary Research. 2022 Apr 1;83(4):317-23. https://iwhealthgroup.com/wp-content/uploads/2025/07/sildenafil-for-treatment-of-generalized-megaesophagus.pdf